Title:Co-treatment of Astragaloside IV with Vitamin D in Diabetic Peripheral
Neuropathic Rats: Protective Effects and Potential Mechanisms
Volume: 17
Author(s): Fengyan Tang, Bo Zhao, Li Zhang, Faisal Raza*, Hajra Zafar, Shao Zhong*, Lin Li, Wenhua Zhu, Lingna Fang, Bing Lu, Liwen Shen, Ping Guo, Nengxing Yu and Quanmin Li*
Affiliation:
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China
- Department of Endocrinology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, 215399, Jiangsu, China
- Department of Endocrinology, PLA Rocket Force Characteristic Medical Center, 100000, Beijing, China
Keywords:
Combination application, AS-IV, Vit-D, Anti-oxidant, Anti-inflammatory, SCV. Article
Abstract:
Objective:
The potential mechanism underlying the protective effect of Astragaloside IV (AS-IV) co-treatment with 1, 25-dihydroxy-vitamin D (Vit-D) on
neuropathy in diabetic high-fat rats was investigated.
Methods:
The rat diabetic hyperlipidemia (DH) model was established via streptozotocin and a high-fat diet (HFD). After co-treatment (of AS-IV and Vit-D
at respective doses of 50 mg/kg via oral gavage and 30000 IU/kg via intramuscular injection), blood glucose levels, markers of inflammation and
oxidative stress, as well as apoptosis and histopathology were evaluated with appropriate techniques.
Results:
Co-treatment could effectively reduce blood glucose levels substantially (p< 0.01), improve weight loss, and decrease oral glucose tolerance.
Reduced respective sensory and motor nerve conduction velocities in rats were substantially improved (p<0.01) after co-treatment. Also, we
observed obvious improvement in DH-induced injured nerve fiber myelin structure and other organ pathologies in co-treated rats. Besides, we
observed up-regulated expressions of peroxisomal-proliferator activated receptor-alpha (PPAR-α) and Vit-D receptors (VDR) (p< 0.01) through
the western blotting technique. Using the same technique, we also discovered reduced levels of interleukin (IL)1 beta, IL-6, and tumor necrosis
factor-alpha, coupled with increased IL-10 and superoxide dismutase levels (p< 0.01). Importantly, co-treatment could effectively exert antioxidative
and anti-inflammatory effects. Also, co-treatment resulted in the up-regulation of PPAR-α and VDR expressions, inhibition of the
renin–angiotensin–aldosterone system, and promotion of β-cell sensitivity to insulin.
Conclusion:
The combined application of AS-IV and Vit-D exhibited health effects such as anti-oxidation, regulation of inflammatory factors, and promotion of
cell repair, which may be considered as the mechanisms underlying treatment of diabetic peripheral neuropathy and improvement in biochemical
indicators.
